Drug Database
Back to search

Germany· DE-A57-7b9ed37a7434d864

Ultravist-240

A iopromide product containing iopromide, registered in Germany by Bayer Vital Gmbh. The same ATC class is registered in 13 of our 19 countries.

ATC V08AB05

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedUltravist-240ATCV08AB05REGISTER NO.DE-A57-7b9ed37a7434d8…PACKS LISTED0CHECKEDSeptember 30, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about iopromideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Iopromide is registered in 13 of 19 countries.

Countries holding a registration under ATC V08AB05 (iopromide), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 7 of them publish a price we can compare per daily dose
Search iopromide products by name

Iopromide · ATC V08AB05

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

EMA Article 57 (European Union)
Active substance
Iopromide
Manufacturer
Bayer Vital Gmbh
Country
Germany (DE)
ATC code
V08AB05
ATC class
Iopromide
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

232 interactions on record for iopromide.

Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check iopromide against other medicinesHow interaction checks work

Iopromide · interactions on record

232 records

  • 94 severe
  • 55 moderate
  • 83 info

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Amphotericin BA07AA07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Iopromide in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All iopromide products

Authorised across Europe · EMA

The same active substance is authorised in 25 EEA countries. Names it is sold under:

  • Austria · Ultravist
  • Belgium · Ultravist
  • Bulgaria · Ултравист
  • Cyprus · Ultravist 300, Ultravist 370
  • Czechia · Ultravist
  • Denmark · Ultravist
  • Estonia · Ultravist
  • Spain · Ultravist
  • France · Ultravist
  • Greece · Ultravist
  • Croatia · Ultravist
  • Hungary · Ultravist
  • Italy · Ultravist
  • Lithuania · Ultravist
  • Luxembourg · Ultravist
  • Latvia · Ultravist
  • Malta · Ultravist 370
  • Netherlands · Ultravist
  • Norway · Ultravist
  • Poland · Ultravist 300, Ultravist 370
  • Portugal · Ultravist 240, Ultravist 300
  • Romania · Ultravist
  • Sweden · Ultravist
  • Slovenia · Ultravist
  • Slovakia · Ultravist

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b893d5cd-9cd7-4ba9-9ab8-7e6eaaca9b6d
GET /v1/drugs/b893d5cd-9cd7-4ba9-9ab8-7e6eaaca9b6d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Intraarterial Use ,Intrathecal Use ,Intravascular Use ,Intravenous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Iopromide",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}
API referenceMCP serverPlans

See everything about iopromide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console